Guardion Health Sciences, Inc. (NASDAQ:GHSI – Get Rating) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 4,420,000 shares, a growth of 29.6% from the March 15th total of 3,410,000 shares. Based on an average trading volume of 7,085,200 shares, the short-interest ratio is currently 0.6 days.
Institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC grew its position in shares of Guardion Health Sciences by 68.4% during the third quarter. Renaissance Technologies LLC now owns 584,792 shares of the company’s stock worth $743,000 after acquiring an additional 237,501 shares during the last quarter. Morgan Stanley grew its position in shares of Guardion Health Sciences by 2,326.1% during the second quarter. Morgan Stanley now owns 326,987 shares of the company’s stock worth $575,000 after acquiring an additional 313,509 shares during the last quarter. Millennium Management LLC bought a new position in shares of Guardion Health Sciences during the third quarter worth about $106,000. Virtu Financial LLC bought a new position in shares of Guardion Health Sciences during the fourth quarter worth about $40,000. Finally, Two Sigma Advisers LP acquired a new stake in Guardion Health Sciences in the third quarter worth about $31,000. Institutional investors and hedge funds own 12.32% of the company’s stock.
Separately, Maxim Group started coverage on shares of Guardion Health Sciences in a research note on Tuesday, March 8th. They set a “buy” rating and a $0.60 target price for the company.
About Guardion Health Sciences (Get Rating)
Guardion Health Sciences, Inc, together with its subsidiaries, operates as a specialty health sciences company in the United States. It operates in two segments, Medical Foods and Nutraceuticals, and Medical Devices. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma.
- Get a free copy of the StockNews.com research report on Guardion Health Sciences (GHSI)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
Receive News & Ratings for Guardion Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardion Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.